hydroxyurea has been researched along with lovastatin in 13 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 2 (15.38) | 18.2507 |
| 2000's | 4 (30.77) | 29.6817 |
| 2010's | 7 (53.85) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Benz, RD; Contrera, JF; Kruhlak, NL; Matthews, EJ; Weaver, JL | 1 |
| Lombardo, F; Obach, RS; Waters, NJ | 1 |
| Chupka, J; El-Kattan, A; Feng, B; Miller, HR; Obach, RS; Troutman, MD; Varma, MV | 1 |
| Barnes, JC; Bradley, P; Day, NC; Fourches, D; Reed, JZ; Tropsha, A | 1 |
| Chang, G; El-Kattan, A; Miller, HR; Obach, RS; Rotter, C; Steyn, SJ; Troutman, MD; Varma, MV | 1 |
| Ekins, S; Williams, AJ; Xu, JJ | 1 |
| Chen, M; Fang, H; Liu, Z; Shi, Q; Tong, W; Vijay, V | 1 |
| Afshari, CA; Chen, Y; Dunn, RT; Hamadeh, HK; Kalanzi, J; Kalyanaraman, N; Morgan, RE; van Staden, CJ | 1 |
| Chen, M; Hu, C; Suzuki, A; Thakkar, S; Tong, W; Yu, K | 1 |
| Baetta, R; Battaini, F; Bergamaschi, S; Davegna, C; De Renzis, MR; Fumagalli, R; Govoni, S; Soma, MR | 1 |
| Chan, PC; Lafrenière, R; Parsons, HG | 1 |
| Doroshenko, N; Doroshenko, P; Sabanov, V | 1 |
| Chou, RC; Langan, TJ; Li, V; Rodgers, KR | 1 |
1 review(s) available for hydroxyurea and lovastatin
| Article | Year |
|---|---|
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
Topics: Chemical and Drug Induced Liver Injury; Databases, Factual; Drug Labeling; Humans; Pharmaceutical Preparations; Risk | 2016 |
12 other study(ies) available for hydroxyurea and lovastatin
| Article | Year |
|---|---|
Assessment of the health effects of chemicals in humans: II. Construction of an adverse effects database for QSAR modeling.
Topics: Adverse Drug Reaction Reporting Systems; Artificial Intelligence; Computers; Databases, Factual; Drug Prescriptions; Drug-Related Side Effects and Adverse Reactions; Endpoint Determination; Models, Molecular; Quantitative Structure-Activity Relationship; Software; United States; United States Food and Drug Administration | 2004 |
Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.
Topics: Blood Proteins; Half-Life; Humans; Hydrogen Bonding; Infusions, Intravenous; Pharmacokinetics; Protein Binding | 2008 |
Physicochemical determinants of human renal clearance.
Topics: Humans; Hydrogen Bonding; Hydrogen-Ion Concentration; Hydrophobic and Hydrophilic Interactions; Kidney; Metabolic Clearance Rate; Molecular Weight | 2009 |
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.
Topics: Animals; Chemical and Drug Induced Liver Injury; Cluster Analysis; Databases, Factual; Humans; MEDLINE; Mice; Models, Chemical; Molecular Conformation; Quantitative Structure-Activity Relationship | 2010 |
Physicochemical space for optimum oral bioavailability: contribution of human intestinal absorption and first-pass elimination.
Topics: Administration, Oral; Biological Availability; Humans; Intestinal Absorption; Pharmaceutical Preparations | 2010 |
A predictive ligand-based Bayesian model for human drug-induced liver injury.
Topics: Bayes Theorem; Chemical and Drug Induced Liver Injury; Humans; Ligands | 2010 |
FDA-approved drug labeling for the study of drug-induced liver injury.
Topics: Animals; Benchmarking; Biomarkers, Pharmacological; Chemical and Drug Induced Liver Injury; Drug Design; Drug Labeling; Drug-Related Side Effects and Adverse Reactions; Humans; Pharmaceutical Preparations; Reproducibility of Results; United States; United States Food and Drug Administration | 2011 |
A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.
Topics: Animals; ATP Binding Cassette Transporter, Subfamily B; ATP Binding Cassette Transporter, Subfamily B, Member 11; ATP-Binding Cassette Transporters; Biological Transport; Chemical and Drug Induced Liver Injury; Cluster Analysis; Drug-Related Side Effects and Adverse Reactions; Humans; Liver; Male; Multidrug Resistance-Associated Proteins; Pharmacokinetics; Rats; Rats, Sprague-Dawley; Recombinant Proteins; Risk Assessment; Risk Factors; Toxicity Tests | 2013 |
PKC activity in rat C6 glioma cells: changes associated with cell cycle and simvastatin treatment.
Topics: Animals; Astrocytoma; Cell Cycle; Demecolcine; Glioma; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hydroxyurea; Lovastatin; Mevalonic Acid; Protein Kinase C; Rats; Simvastatin; Tumor Cells, Cultured | 1994 |
Lovastatin increases surface low density lipoprotein receptor expression by retarding the receptor internalization rate in proliferating lymphocytes.
Topics: Carbocyanines; Cell Division; Endocytosis; Flow Cytometry; Fluorescent Dyes; Genistein; Hydroxyurea; Interleukin-2; Isoflavones; Lipoproteins, LDL; Lovastatin; Lymphocyte Activation; Lymphocytes; Mevalonic Acid; Monensin; Phytohemagglutinins; Receptors, Interleukin-2; Receptors, LDL | 1997 |
Cell cycle-related changes in regulatory volume decrease and volume-sensitive chloride conductance in mouse fibroblasts.
Topics: Animals; Aphidicolin; Cell Cycle; Cell Division; Cell Line; Cell Size; Chlorides; Culture Media, Serum-Free; Cytarabine; Electric Conductivity; Enzyme Inhibitors; Fibroblasts; Hydroxyurea; Ion Transport; Lovastatin; Mice; Mimosine; Osmotic Pressure; Paclitaxel; Patch-Clamp Techniques | 2001 |
Differential and kinetic effects of cell cycle inhibitors on neoplastic and primary astrocytes.
Topics: Animals; Astrocytes; Cell Cycle; Cell Line, Tumor; Cell Proliferation; Cells, Cultured; DNA; Hydroxyurea; Kinetics; Lovastatin; Neoplasms; Rats, Sprague-Dawley; Serum | 2016 |